Roivant Sciences (NASDAQ:ROIV – Get Free Report) and Annovis Bio (NYSE:ANVS – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Profitability
This table compares Roivant Sciences and Annovis Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Roivant Sciences | 3,827.42% | -14.65% | -13.19% |
| Annovis Bio | N/A | -876.22% | -311.00% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Roivant Sciences and Annovis Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Roivant Sciences | 0 | 1 | 7 | 0 | 2.88 |
| Annovis Bio | 0 | 1 | 4 | 1 | 3.00 |
Valuation and Earnings
This table compares Roivant Sciences and Annovis Bio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Roivant Sciences | $129.13 million | 65.90 | $4.35 billion | $5.65 | 2.07 |
| Annovis Bio | N/A | N/A | -$56.20 million | ($4.46) | -1.21 |
Roivant Sciences has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Comparatively, 32.3% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Roivant Sciences has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
Summary
Roivant Sciences beats Annovis Bio on 9 of the 14 factors compared between the two stocks.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
About Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
